Skip to main content

Table 1 Semi-structured discussion guide

From: Barriers to scaling up hepatitis C treatment in Malaysia: a qualitative study with key stakeholders

Scope of discussion Questions and probes Dimension of treatment access
Screening and outreach to key populations Who are the key populations of HCV in your area, and what have been the challenges in linking them to care?
(Probes: distance, movement restriction)
Geographical accessibility
What have been the challenges in HCV screening and case-finding in your setting?
(Probes: patient load, staffing, facilities, system, knowledge, communication, culture)
Availability/
acceptability
What have been the challenges in referring individuals with a positive rapid screening test result to other settings for confirmatory testing and further management?
(Probes: logistical barriers, patient load, staffing, facilities, system, communication, culture)
Geographical accessibility
availability/
acceptability
Diagnosis and laboratory tests What have been the challenges in HCV diagnosis and laboratory tests in your setting?
(Probes: patient load, staffing, facilities, system)
Availability
What have been the challenges in communicating the test results with other settings?
(Probes: system, turnaround time, communication, culture)
Availability/
acceptability
Supply sustainability and inventory management Are there any issues with the supply of direct-acting antivirals, rapid screening test kits and laboratory test reagents in your setting?
(Probes: cost, budget, amounts)
Availability/ affordability
Pharmacological treatment and follow-up What have been the challenges in initiating HCV treatment and evaluating its outcomes in your setting?
(Probes: awareness, attitude, refusal, system, skills)
Availability/
acceptability
Although the treatment is provided free of charge, do you think there are any other indirect costs discouraging people living with HCV from receiving treatment?
(Probes: multiple visits, transportation)
Affordability
HCV hepatitis C virus